ABCL
Price
$3.51
Change
+$0.10 (+2.93%)
Updated
Nov 21 closing price
Capitalization
1.05B
93 days until earnings call
Intraday BUY SELL Signals
EDIT
Price
$2.42
Change
-$0.05 (-2.02%)
Updated
Nov 21 closing price
Capitalization
236.24M
88 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs EDIT

Header iconABCL vs EDIT Comparison
Open Charts ABCL vs EDITBanner chart's image
AbCellera Biologics
Price$3.51
Change+$0.10 (+2.93%)
Volume$3.5M
Capitalization1.05B
Editas Medicine
Price$2.42
Change-$0.05 (-2.02%)
Volume$1.98M
Capitalization236.24M
ABCL vs EDIT Comparison Chart in %
ABCL
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ABCL vs. EDIT commentary
Nov 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and EDIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 23, 2025
Stock price -- (ABCL: $3.51 vs. EDIT: $2.42)
Brand notoriety: ABCL and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 64% vs. EDIT: 71%
Market capitalization -- ABCL: $1.05B vs. EDIT: $236.24M
ABCL [@Biotechnology] is valued at $1.05B. EDIT’s [@Biotechnology] market capitalization is $236.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABCL and EDIT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 6 bearish.
  • EDIT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -4.88% price change this week, while EDIT (@Biotechnology) price change was -6.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +62.87%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 24, 2026.

EDIT is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.05B) has a higher market cap than EDIT($236M). EDIT YTD gains are higher at: 90.551 vs. ABCL (19.795). ABCL has higher annual earnings (EBITDA): -197.92M vs. EDIT (-227.72M). ABCL has more cash in the bank: 553M vs. EDIT (179M). EDIT has less debt than ABCL: EDIT (21.1M) vs ABCL (142M). EDIT has higher revenues than ABCL: EDIT (38.9M) vs ABCL (32.9M).
ABCLEDITABCL / EDIT
Capitalization1.05B236M445%
EBITDA-197.92M-227.72M87%
Gain YTD19.79590.55122%
P/E RatioN/AN/A-
Revenue32.9M38.9M85%
Total Cash553M179M309%
Total Debt142M21.1M673%
FUNDAMENTALS RATINGS
EDIT: Fundamental Ratings
EDIT
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLEDIT
RSI
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 6 days ago
86%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
EDIT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FLUAX29.260.44
+1.53%
Fidelity Advisor Stk Selec Lg Cp Val A
SMINX13.220.18
+1.38%
SEI Tax-Managed Intl Mgd Vol F (SIMT)
NPRTX51.320.62
+1.22%
Neuberger Berman Large Cap Value Inv
SPMVX9.100.03
+0.33%
Invesco SteelPath MLP Select 40 R5
LEQIX13.120.03
+0.23%
LoCorr Dynamic Opportunity I

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+2.93%
RXRX - ABCL
58%
Loosely correlated
+8.31%
ABSI - ABCL
56%
Loosely correlated
+5.78%
VCYT - ABCL
56%
Loosely correlated
+7.74%
CRSP - ABCL
55%
Loosely correlated
+1.91%
DNA - ABCL
52%
Loosely correlated
+4.48%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with AXON. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-2.02%
AXON - EDIT
52%
Loosely correlated
+0.46%
CRSP - EDIT
52%
Loosely correlated
+1.91%
VCYT - EDIT
49%
Loosely correlated
+7.74%
PRME - EDIT
49%
Loosely correlated
-1.63%
ABCL - EDIT
48%
Loosely correlated
+2.93%
More